Literature DB >> 33724502

Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.

Gyongyi Szabo1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33724502      PMCID: PMC9272484          DOI: 10.1002/hep.31805

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  10 in total

1.  MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.

Authors:  Yong He; Seonghwan Hwang; Yan Cai; Seung-Jin Kim; Mingjiang Xu; Dingcheng Yang; Adrien Guillot; Dechun Feng; Wonhyo Seo; Xin Hou; Bin Gao
Journal:  Hepatology       Date:  2019-06-05       Impact factor: 17.425

Review 2.  Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.

Authors:  Gyongyi Szabo; Fatemeh Momen-Heravi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-21       Impact factor: 46.802

3.  High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: Role of scavenger receptor BI-mediated lipid transfer.

Authors:  Luisa F Cuesta Torres; Wanying Zhu; Gustav Öhrling; Rasmus Larsson; Mili Patel; Carrie B Wiese; Kerry-Anne Rye; Kasey C Vickers; Fatiha Tabet
Journal:  Atherosclerosis       Date:  2019-05-02       Impact factor: 5.162

Review 4.  Triggering and resolution of inflammation in NASH.

Authors:  Susanne Schuster; Daniel Cabrera; Marco Arrese; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-06       Impact factor: 46.802

5.  Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.

Authors:  Xin Hou; Shi Yin; Ruixue Ren; Siqi Liu; Liang Yong; Yuxiao Liu; Yu Li; Ming-Hua Zheng; George Kunos; Bin Gao; Hua Wang
Journal:  Hepatology       Date:  2021-04-27       Impact factor: 17.298

6.  Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.

Authors:  Michal Ganz; Terence N Bukong; Timea Csak; Banishree Saha; Jin-Kyu Park; Aditya Ambade; Karen Kodys; Gyongyi Szabo
Journal:  J Transl Med       Date:  2015-06-16       Impact factor: 5.531

7.  Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS.

Authors:  Fatemeh Momen-Heravi; Shashi Bala; Karen Kodys; Gyongyi Szabo
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

Review 8.  Role of Hedgehog Signaling Pathway in NASH.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Int J Mol Sci       Date:  2016-06-01       Impact factor: 5.923

Review 9.  Role of miR-223 in the pathophysiology of liver diseases.

Authors:  Dan Ye; Tianbao Zhang; Guohua Lou; Yanning Liu
Journal:  Exp Mol Med       Date:  2018-09-26       Impact factor: 8.718

10.  A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice.

Authors:  Xiaobo Wang; Mark R Sommerfeld; Kerstin Jahn-Hofmann; Bishuang Cai; Aveline Filliol; Helen E Remotti; Robert F Schwabe; Aimo Kannt; Ira Tabas
Journal:  Hepatol Commun       Date:  2019-07-23
  10 in total
  3 in total

Review 1.  Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.

Authors:  Ki Wung Chung; Ye Eun Cho; Seung-Jin Kim; Seonghwan Hwang
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 4.946

Review 2.  Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.

Authors:  Seonghwan Hwang; Hwayoung Yun; Sungwon Moon; Ye Eun Cho; Bin Gao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-11       Impact factor: 5.555

3.  Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets.

Authors:  Fatemeh Kazeminasab; Maryam Baharlooie; Kamran Ghaedi
Journal:  PPAR Res       Date:  2022-09-17       Impact factor: 4.385

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.